Skip to content
Tolazoline
Priscoline (tolazoline) is a small molecule pharmaceutical. Tolazoline was first approved as Priscoline on 1985-02-22. It is used to treat arteriosclerosis obliterans, causalgia, peripheral vascular diseases, persistent fetal circulation syndrome, and raynaud disease amongst others in the USA. The pharmaceutical is active against alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
nervous system diseasesD009422
cardiovascular diseasesD002318
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tolazoline hydrochloride
Tradename
Company
Number
Date
Products
PRISCOLINENovartisN-006403 DISCN1985-02-22
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
arteriosclerosis obliteransEFO_1000820D001162—
causalgiaEFO_1000854D002422—
peripheral vascular diseasesEFO_0003875D016491I73.9
persistent fetal circulation syndromeEFO_1001103D010547P29.3
raynaud diseaseEFO_1001145D011928I73.0
spasm—D013035M62.83
systemic sclerodermaEFO_0000717D012595M34
thromboangiitis obliteransEFO_1001211D013919I73.1
thrombophlebitisHP_0004418D013924—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C04: Peripheral vasodilators
— C04A: Peripheral vasodilators
— C04AB: Imidazoline derivatives, peripheral vasodilators
— C04AB02: Tolazoline
M: Musculo-skeletal system drugs
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AX: Other topical products for joint and muscular pain in atc
— M02AX02: Tolazoline
HCPCS
Code
Description
J2670
Injection, tolazoline hcl, up to 25 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTOLAZOLINE
INNtolazoline
Description
Tolazoline is a member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group. It has a role as an alpha-adrenergic antagonist, an antihypertensive agent and a vasodilator agent.
Classification
Small molecule
Drug classantihistamines/local vasoconstrictors (antazoline type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
c1ccc(CC2=NCCN2)cc1
Identifiers
PDB—
CAS-ID59-98-3
RxCUI10634
ChEMBL IDCHEMBL770
ChEBI ID28502
PubChem CID5504
DrugBankDB00797
UNII IDCHH9H12AQ3 (ChemIDplus, GSRS)
Target
Agency Approved
ADRA2B
ADRA2B
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
151
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Q9BZK0
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 989 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6 adverse events reported
View more details